Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an update.
Hansoh Pharmaceutical Group Company Limited reported significant financial growth for the year ended December 31, 2024, with a 21.3% increase in revenue to approximately RMB12,261 million. This growth was primarily driven by a 38.1% increase in revenue from innovative drugs and collaborative products, which now constitute 77.3% of total revenue. The company’s net profit also rose by 33.4% to approximately RMB4,372 million. Key developments during the year included clinical trial approvals for several self-developed innovative drugs and strategic licensing agreements, enhancing the company’s product pipeline and market reach.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a leading innovation-driven pharmaceutical enterprise in China, focusing on major disease therapeutic areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmunity. The company has launched seven innovative drugs, forming a rich product pipeline, with innovative drugs and collaborative products accounting for a significant portion of its revenue.
YTD Price Performance: 21.82%
Average Trading Volume: 6,198,327
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$117.5B
For detailed information about 3692 stock, go to TipRanks’ Stock Analysis page.